Document Detail

Restenosis of the CYPHER-Select, TAXUS-Express, and Polyzene-F nanocoated cobalt-chromium stents in the minipig coronary artery model.
MedLine Citation:
PMID:  18095019     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To date no direct experimental comparison between the CYPHER-Select and TAXUS-Express stents is available. Therefore, we investigated late in-stent stenosis, thrombogenicity, and inflammation, comparing the CYPHER-Select, TAXUS-Express, and custom-made cobalt chromium Polyzene-F nanocoated stents (CCPS) in the minipig coronary artery model. METHODS: The three stent types were implanted in the right coronary artery of 30 minipigs. The primary endpoint was in-stent stenosis assessed by quantitative angiography and microscopy. Secondary endpoints were inflammation and thrombogenicity evaluated by scores for inflammation and immunoreactivity (C-reactive protein and transforming growth factor beta). Follow-up was at 4 and 12 weeks. RESULTS: Stent placement was successful in all animals; no thrombus deposition occurred. Quantitative angiography did not depict statistically significant differences between the three stent types after 4 and 12 weeks. Quantitative microscopy at 4 weeks showed a statistically significant thicker neointima (p = 0.0431) for the CYPHER (105.034 +/- 62.52 microm) versus the TAXUS (74.864 +/- 66.03 microm) and versus the CCPS (63.542 +/- 39.57 microm). At 12 weeks there were no statistically significant differences. Inflammation scores at 4 weeks were significantly lower for the CCPS and CYPHER compared with the TAXUS stent (p = 0.0431). After 12 weeks statistical significance was only found for the CYPHER versus the TAXUS stent (p = 0.0431). The semiquantitative immunoreactivity scores for C-reactive protein and transforming growth factor beta showed no statistically significant differences between the three stent types after 4 and 12 weeks. CONCLUSIONS: The CCPS provided effective control of late in-stent stenosis and thrombogenicity in this porcine model compared with the two drug-eluting stents. Its low inflammation score underscores its noninflammatory potential and might explain its equivalence to the two DES.
Boris Radeleff; Heidi Thierjung; Ulrike Stampfl; Sibylle Stampfl; Ruben Lopez-Benitez; Christof Sommer; Irina Berger; Goetz M Richter
Related Documents :
10467079 - Successful treatment of a bifurcation lesion with the carina bard stent: a case report.
10785719 - Spontaneous resolution of pseudo-narrowing after coronary artery stenting.
18316839 - Brachial artery perforation repaired with percutaneous transfemoral covered stent deplo...
20040479 - Reopening acutely occluded cavopulmonary connections in infants and children.
17538289 - Assessment of coronary stent in vitro on multislice computed tomography angiography: im...
17042669 - Iliac anastomotic stenting with a sirolimus-eluting biodegradable poly-l-lactide stent:...
17670259 - Bullet embolism to the pulmonary artery.
6821759 - Major mediastinal vascular injuries.
23799559 - Usefulness of the global echo-doppler score (geds) in selection of patients with mitral...
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2007-12-19
Journal Detail:
Title:  Cardiovascular and interventional radiology     Volume:  31     ISSN:  1432-086X     ISO Abbreviation:  Cardiovasc Intervent Radiol     Publication Date:    2008 Sep-Oct
Date Detail:
Created Date:  2008-09-12     Completed Date:  2009-01-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8003538     Medline TA:  Cardiovasc Intervent Radiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  971-80     Citation Subset:  IM    
Department of Radiology, University Heidelberg, INF 110, 69120, Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary / instrumentation,  methods
Biopsy, Needle
Blood Vessel Prosthesis
Chromium / pharmacology
Coated Materials, Biocompatible
Cobalt / pharmacology
Coronary Disease / pathology,  therapy*
Coronary Restenosis / pathology*
Disease Models, Animal
Drug-Eluting Stents*
Prosthesis Design
Prosthesis Failure*
Random Allocation
Sensitivity and Specificity
Sirolimus / therapeutic use
Swine, Miniature
Reg. No./Substance:
0/Coated Materials, Biocompatible; 0/Polymers; 109581-93-3/Tacrolimus; 53123-88-9/Sirolimus; 7440-47-3/Chromium; 7440-48-4/Cobalt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fungal diversity of Norway spruce litter: effects of site conditions and premature leaf fall caused ...
Next Document:  The carbon footprint of laparoscopic surgery: should we offset?